The Karyopharm Medical Affairs Team is excited to announce that we now have resources available for Medical Education Grants – we are committed to collaborate with the US healthcare community and support for unbiased, evidence- based, independent medical education. For more information, visit the Karyopharm Medical Affairs website: https://lnkd.in/gGjnGDzJ?#BelieversinScience
Karyopharm Medical Affairs
制药业
Karyopharm Medical Affairs delivers timely communications of medical scientific information intended for US HCPs.
关于我们
The goal of the Karyopharm Medical Affairs LinkedIn page is to deliver timely communication of medical and scientific information regarding Karyopharm Therapeutics, Inc. products and the relevant diseases with US healthcare professionals (HCPs). We will share information about scientific data presented at medical congresses, published in peer-reviewed journals, clinical studies that are newly posted on clinicaltrials.gov, clinical studies that are recruiting, and relevant disease-related information. Extraordinary persistence, grit and unwavering passion drive our commitment to the delivery of scientific innovation. It’s the extraordinary strength and courage of patients who fuel our continued pursuit. By engaging with the Karyopharm Medical Affairs LinkedIn page, you confirm that you are a US HCP, and agree to receive information from Karyopharm Medical Affairs LinkedIn page according to the Terms & Conditions provided by LinkedIn (www.dhirubhai.net/legal/user-agreement). Content posted on this account should not be shared outside the US and contents not posted by Karyopharm Therapeutics do not reflect our views or opinions and we do not guarantee their accuracy or reliability. Our posts are intended to share scientific information and should not be viewed as medical advice and may include content about uses of Karyopharm products that may not be approved by the FDA. Karyopharm cannot make any clinical recommendations or provide medical treatment advice. Any information provided on this site should not take the place of your own independent medical judgment. If you have any questions about a specific Karyopharm Therapeutics product, please contact Karyopharm Therapeutics Medical Information at [email protected]. Please report any side effects from any of our products or product quality complaints by calling 1-888-209-9326. Channel run by https://karyopharm.com/
- 网站
-
https://www.karyopharmmedicalaffairs.com/
Karyopharm Medical Affairs的外部链接
- 所属行业
- 制药业
- 规模
- 201-500 人
- 总部
- Newton
- 类型
- 上市公司
- 创立
- 2008
- 领域
- oncology、pharmaceutical、biotech、multiple myeloma、lymphoma、solid tumors、endometrial cancer、clinical research、research、clinical trials、drug discovery、medical和healthcare
地点
-
主要
获取路线
85 Wells Avenue
US，Newton，MA 02459
动态
-
ATTENTION US HCPs – Medical Information specific for #MultipleMyeloma is now available on our GMSA website to help support US HCPs. For more information, visit the Karyopharm Medical Affairs website: https://lnkd.in/gawgC2U7 #BelieversinScience
-
ATTENTION US HCPs – We are excited to announce that our GMSA website now includes investigator-sponsored trial resources and areas of research interest! For more information, visit the Karyopharm Medical Affairs website: https://lnkd.in/gEXmP8iT #BelieversinScience #KPTI
-
The Karyopharm Medical Affairs team had a wonderful time at the 16th International Congress on Myeloproliferative Neoplasms in Brooklyn, New York! For US HCPs who missed us, visit the Karyopharm Medical Affairs website Congresses & Publications section to learn more. https://lnkd.in/e_wBcybv #clinicaltrials #BelieversinScience
-
The Karyopharm Medical Affairs Team just attended another inspiring conference on October 16-19, 2024 in beautiful New York City! #LLMCongress2024?? ? We were thrilled to present a poster presentation on real-world use of an XPO1 inhibitor in #MultipleMyeloma. ? ? For US HCPs who missed us at #LLMCongress2024, visit the Karyopharm Medical Affairs website Congresses & Publications section to learn more. https://lnkd.in/e_wBcybv #clinicaltrials #BelieversinScience?
-
What an exciting time at the IGCS Annual Global Meeting in Dublin, Ireland on October 16-18, 2024!?? ? We were honored to present an oral plenary presentation on the safety and efficacy of our XPO1 inhibitor in #EndometrialCancer.?? ? For US HCPs who missed us at #IGCS24, visit the Karyopharm Medical Affairs website Congresses & Publications section to learn more. https://lnkd.in/e_wBcybv #clinicaltrials #BelieversinScience?
-
US HCPs: The Karyopharm Medical Affairs Team is attending the 16th International Congress on Myeloproliferative Neoplasms in Brooklyn, New York this week!? Please stop by our medical booth and poster to learn more about our latest #Myelofibrosis research. #BelieversinScience #Clinicaltrials
-
-
US HCPs: The Karyopharm Medical Affairs team is here at #IGCS24 in Dublin, Ireland. We are excited for the opportunity to reconnect with experts in #EndometrialCancer and learn about the latest research in the field!??
-
-
US HCPs! Join us for our Innovation Theater Presentation at the #LLMCongress2024!?? ? The Karyopharm Medical Affairs Team invites you to a presentation on XPO-1 inhibition in Relapsed/Refractory Multiple Myeloma in the Empire West Ballroom at the Sheraton New York Times Square on October 18th at 11:55 am #MultipleMyeloma #BelieversinScience?
-
-
The KPTI Medical Affairs team is committed to #EndometrialCancer. For US healthcare providers attending IGCS (October 16-18th 2024), stop by the Karyopharm Medical Affairs Booth (#19) and attend our Plenary Oral Presentation to see the latest data from our Phase 3 trial in patients with TP53 wild-type #EndometrialCancer #BelieversinScience?
-